Aducanumab, the first Alzheimer’s-modifying therapy, submitted to the FDA. Can Biogen recover from their errors?
“If you have a loved one with dementia, you know this can be a heart-wrenching process. You cannot change the person. . . . You have to meet them where they are, roll with it, and speak with love and patience. It was a pleasure to speak to Dr. David Weisman, a neurologist.”
The field of MS research has had amazing success in the last two decades.
Multiple sclerosis (MS) is an autoimmune disease in which the immune system misrecognizes part of the brain called myelin.
Early on in their careers, two neurologists became involved in advocacy issues on behalf of neurology on a national, regional, and local level.
One day, one of the trials in Alzheimer’s disease will be positive. We think this trial may already be underway.
Dr. Klein has been appointed Chair of the Medical Economics and Practice committee, as well as serving on the Board of Directors.
We continue to fight for a disease modifying treatment in Alzheimer’s disease despite recent setbacks.
Dr. Klein has published an editorial opposing a well-intentioned but overbearing new law proposed by the Philadelphia City Council.
The FDA recently allowed 23andMe to release health risk info to customers. “This is a travesty,” he said in an interview.